Dataset Information

Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies.

ABSTRACT: Epidemiological studies have clarified the potential associations between regular aspirin use and cancers. However, it remains controversial on whether aspirin use decreases the risk of cancers risks. Therefore, we conducted an updated meta-analysis to assess the associations between aspirin use and cancers.The PubMed, Embase, and Web of Science databases were systematically searched up to March 2017 to identify relevant studies. Relative risks (RRs) with 95% confidence intervals (CIs) were used to assess the strength of associations.A total of 218 studies with 309 reports were eligible for this meta-analysis. Aspirin use was associated with a significant decrease in the risk of overall cancer (RR?=?0.89, 95% CI: 0.87-0.91), and gastric (RR?=?0.75, 95% CI: 0.65-0.86), esophageal (RR?=?0.75, 95% CI: 0.62-0.89), colorectal (RR?=?0.79, 95% CI: 0.74-0.85), pancreatic (RR?=?0.80, 95% CI: 0.68-0.93), ovarian (RR?=?0.89, 95% CI: 0.83-0.95), endometrial (RR?=?0.92, 95% CI: 0.85-0.99), breast (RR?=?0.92, 95% CI: 0.88-0.96), and prostate (RR?=?0.94, 95% CI: 0.90-0.99) cancers, as well as small intestine neuroendocrine tumors (RR?=?0.17, 95% CI: 0.05-0.58).These findings suggest that aspirin use is associated with a reduced risk of gastric, esophageal, colorectal, pancreatic, ovarian, endometrial, breast, and prostate cancers, and small intestine neuroendocrine tumors.

SUBMITTER: Qiao Y

PROVIDER: S-EPMC5851082 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies.

Qiao Yan Y Yang Tingting T Gan Yong Y Li Wenzhen W Wang Chao C Gong Yanhong Y Lu Zuxun Z

BMC cancer 20180313 1

<h4>Background</h4>Epidemiological studies have clarified the potential associations between regular aspirin use and cancers. However, it remains controversial on whether aspirin use decreases the risk of cancers risks. Therefore, we conducted an updated meta-analysis to assess the associations between aspirin use and cancers.<h4>Methods</h4>The PubMed, Embase, and Web of Science databases were systematically searched up to March 2017 to identify relevant studies. Relative risks (RRs) with 95% c ...[more]

PMID: 29534696

Similar Datasets

Project description:BackgroundEpidemiological evidence suggests that use of aspirin after the diagnosis of colorectal cancer can lengthen survival. However, the supporting data vary between studies, and this hypothesis remains controversial. We conducted a meta-analysis to provide a quantitative assessment of the association between use of aspirin after diagnosis of colorectal cancer and patient survival.MethodsWe searched the Medline and Embase databases up to April 2014 to identify studies related to aspirin use after diagnosis and all-cause mortality or colorectal cancer-specific mortality. Summary effect estimates with 95% confidence intervals (CIs) were derived using a fixed or random effects model, depending on the heterogeneity between the included studies.ResultsSeven epidemiologic studies that consisted of six cohort studies and one nested case-control study were included in this meta-analysis. The hazard ratio (HR) of the association between aspirin use after colorectal cancer diagnosis and overall mortality, which was reported in five studies, was 0.74 (95% CI, 0.62-0.89) using a random model (heterogeneity test P=0.003, I(2)=75.3%), and for colorectal cancer-specific mortality (four studies), it was 0.75 (95% CI, 0.51-1.10) using a random model (heterogeneity test P=0.001, I(2)=84.1%). In addition, we analysed postdiagnosis aspirin use according to whether aspirin was also used before diagnosis. The HR for the overall mortality of patients who did not use aspirin before diagnosis, which was reported in four studies, was 0.84 (95% CI, 0.70-1.00), and for colorectal cancer-specific mortality (three studies), it was 0.79 (95% CI, 0.61-1.02). For those who did use aspirin before diagnosis, the HR for overall mortality (four studies) was 0.88 (95% CI, 0.83-0.93), and for colorectal cancer-specific mortality (three studies), it was 0.80 (95% CI, 0.59-1.09). Subgroup analysis showed that use of aspirin after diagnosis was associated with longer overall survival among patients with the variant PIK3CA gene but not for those with wild-type PIK3CA.ConclusionsBased on current evidence, the use of aspirin after diagnosis does not reduce colorectal cancer-specific mortality, but it does reduce all-cause mortality for colorectal cancer patients.

Dataset Information

Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies.

Publications

Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets